Executives On The Move: Departures From Big Pharmas Novo Nordisk, J&J And Lilly To Oncology-Focused Firms
Executive Summary
A new COO arrives from Novo Nordisk at Danish immunotherapy firm CytoVac and a J&J Vice President becomes CEO of Xcovery, developer of therapies for advanced tumors. From Eli Lilly, DNA damage response company Artios Pharma adds a CMO.